These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 11762825)
1. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. Saikia TK; Menon H; Advani SH Ann Oncol; 2001 Oct; 12(10):1493-4. PubMed ID: 11762825 [No Abstract] [Full Text] [Related]
2. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642 [TBL] [Abstract][Full Text] [Related]
3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061 [TBL] [Abstract][Full Text] [Related]
4. Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis. Laszlo D; Rabascio C; Andreola G; Pruneri G; Raia V; Calabrese L; Radice D; Saronni L; Martinelli G Leuk Lymphoma; 2007 Feb; 48(2):437-8. PubMed ID: 17325914 [No Abstract] [Full Text] [Related]
5. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187 [TBL] [Abstract][Full Text] [Related]
6. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626 [No Abstract] [Full Text] [Related]
7. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705 [TBL] [Abstract][Full Text] [Related]
9. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. King KM; Younes A Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023 [TBL] [Abstract][Full Text] [Related]
10. Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data. Andemariam B; Leonard JP Clin Lymphoma Myeloma; 2006 Oct; 7 Suppl 1():S20-3. PubMed ID: 17101069 [TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Leonard JP; Friedberg JW; Younes A; Fisher D; Gordon LI; Moore J; Czuczman M; Miller T; Stiff P; Cheson BD; Forero-Torres A; Chieffo N; McKinney B; Finucane D; Molina A Ann Oncol; 2007 Jul; 18(7):1216-23. PubMed ID: 17470451 [TBL] [Abstract][Full Text] [Related]
12. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Collins-Burow B; Santos ES Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647 [TBL] [Abstract][Full Text] [Related]
13. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Korte W; Jost C; Cogliatti S; Hess U; Cerny T Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345 [No Abstract] [Full Text] [Related]
14. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. Seiler T; Hiddemann W; Dreyling M Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916 [TBL] [Abstract][Full Text] [Related]
15. [Proteins in haematology]. Clarenbach RE; Mey U Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523 [TBL] [Abstract][Full Text] [Related]
16. Rituximab immunotherapy for non-Hodgkin's lymphoma. White CA Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310 [TBL] [Abstract][Full Text] [Related]
18. What is the role of maintenance rituximab in follicular NHL? Maloney DG Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281 [TBL] [Abstract][Full Text] [Related]
19. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. Blombery P; Prince HM; Levinson M; Pianko S; Maxwell E; Bhathal P J Clin Oncol; 2011 Feb; 29(5):e110-2. PubMed ID: 21098319 [No Abstract] [Full Text] [Related]
20. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Berinstein NL; Grillo-López AJ; White CA; Bence-Bruckler I; Maloney D; Czuczman M; Green D; Rosenberg J; McLaughlin P; Shen D Ann Oncol; 1998 Sep; 9(9):995-1001. PubMed ID: 9818074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]